Tell us what you think about Healio
Sign in for a personal experience.
Customized content served to meet your interests.
ORLANDO, Fla. — Eric J. Lawitz, MD, of the Texas Liver Institute at the University of Texas, San Antonio, discusses his late-breaking poster “SVR Results of a Once Daily Regimen of Simeprevir (Tmc435) Plus Sofosbuvir (Gs-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders” at Digestive Disease Week 2013.
He reports encouraging results for SVR among patients who underwent a 12-week regimen of simeprevir and sofosbuvir and were previously null responders to peginterferon and ribavirin.
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.
See related story »
View past polls »
©2013 All Rights Reserved.